Financial Performance - Operating revenue for the first nine months of 2024 reached CNY 223,826,491.38, a 31.83% increase from CNY 169,781,662.69 in the same period of 2023[4] - Net profit attributable to shareholders for the first nine months of 2024 was CNY 19,526,091.61, up 54.23% from CNY 12,660,076.62 year-on-year[4] - Basic earnings per share increased by 52.94% to CNY 0.26 for the first nine months of 2024, compared to CNY 0.17 in the same period of 2023[4] - In Q3 2024, operating revenue was CNY 91,517,316.49, representing a 59.01% increase from CNY 57,555,852.54 in Q3 2023[4] - Net profit attributable to shareholders in Q3 2024 surged by 135.22% to CNY 5,678,588.17, compared to CNY 2,414,185.81 in Q3 2023[4] - Total operating revenue for the first nine months of 2024 reached ¥223,826,491.38, a significant increase of 31.8% compared to ¥169,781,662.69 in the same period of 2023[21] - Total operating costs for the same period were ¥201,402,456.95, up 26.6% from ¥159,181,541.57 in 2023[21] - Net profit for the first nine months of 2024 reached ¥21,167,587.14, a significant increase from ¥12,764,111.63 in the same period of 2023, representing a growth of approximately 66.5%[24] - Operating profit for the first nine months of 2024 was ¥25,593,540.83, up from ¥12,889,004.88 in 2023, reflecting an increase of approximately 98.5%[23] Cash Flow - Cash flow from operating activities showed a significant decline, with a net outflow of CNY 12,729,953.33, down 173.88% from a net inflow of CNY 17,230,872.40 in the previous year[4] - The company’s cash and cash equivalents decreased by 63.18% to CNY 18,967,926.25 due to the utilization of raised funds for projects and payments for raw materials[5] - Cash inflow from sales of goods and services was CNY 234,019,482.97, up from CNY 197,947,413.73 in the same period of 2023, reflecting a growth of about 18.2%[25] - The cash outflow for purchasing goods and services was CNY 232,097,518.50, compared to CNY 165,063,324.53 in the previous year, indicating an increase of approximately 40.5%[25] - Cash inflow from investment activities totaled CNY 266,774,071.59, up from CNY 200,206,644.85 in the previous year, marking an increase of about 33.2%[26] - The net cash flow from investment activities was -CNY 13,023,463.82, an improvement from -CNY 39,798,265.70 in the same period of 2023[26] - Cash inflow from financing activities was CNY 28,560,809.00, a decrease from CNY 35,360,785.00 in the previous year, reflecting a decline of approximately 19.9%[26] - The net cash flow from financing activities was -CNY 7,174,678.16, compared to -CNY 23,257,853.78 in the same period of 2023, indicating a reduced outflow[26] Assets and Liabilities - Total assets increased by 8.78% to CNY 492,896,698.71 as of September 30, 2024, compared to CNY 453,093,129.65 at the end of 2023[4] - The company's current assets decreased from 294,402,629.11 yuan at the end of 2023 to 234,863,474.45 yuan, a decline of about 20.2%[15] - The company's total liabilities increased from 59,718,298.80 yuan to 83,114,169.44 yuan, reflecting a rise of about 39.2%[17] - The company’s non-current liabilities totaled 5,229,200.38 yuan, up from 3,874,085.13 yuan, indicating an increase of approximately 35%[17] - The company’s equity attributable to shareholders rose from 393,209,412.92 yuan to 409,173,051.30 yuan, an increase of approximately 4.1%[17] - The accounts receivable increased from 63,263,660.23 yuan to 79,838,351.47 yuan, representing a growth of about 26.3%[15] - The company's inventory increased slightly from 73,931,694.95 yuan to 74,678,189.19 yuan, a growth of about 1%[15] Expenses - Sales expenses surged by 157.66% to ¥2,928,687.34, resulting from an increase in sales personnel and participation in more domestic and international exhibitions[6] - Management expenses grew by 75.81% to ¥10,447,827.51, primarily due to salary increases for management and additional personnel in the U.S. subsidiary[6] - Research and development expenses for the first nine months of 2024 were ¥9,025,240.80, a decrease of 16.0% compared to ¥10,729,104.02 in the same period of 2023[21] - The company reported a credit impairment loss of ¥1,140,300.91 for the first nine months of 2024, compared to a gain of ¥212,535.09 in 2023[23] - The company incurred asset impairment losses of ¥2,002,103.30 in the first nine months of 2024, compared to ¥478,285.04 in 2023, indicating a significant increase in losses[23] Future Plans - The company plans to apply for a credit line of up to 120 million yuan from banks, with actual control and major shareholders providing guarantees as needed[13] - The company plans to expand its market presence and invest in new product development to drive future growth[21]
欧康医药(833230) - 2024 Q3 - 季度财报